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ABSTRACT
Introduction: To explore the effect of maternal fluorinated steroid therapy on fetuses affected
by immune-mediated complete atrio-ventricular block (CAVB) in utero.
Material and methods: Pubmed, Embase, Cinahl, and ClinicalTrials.gov databases were
searched. Only studies reporting the outcome of fetuses with immune CAVB diagnosed on pre-
natal ultrasound without any cardiac malformations and treated with fluorinated steroids com-
pared to those not treated were included. The primary outcome observed was the regression of
CAVB; secondary outcomes were need for pacemaker insertion, overall mortality, defined as the
occurrence of either intrauterine (IUD) or neonatal (NND) death, IUD, NND, termination of preg-
nancy (TOP). Furthermore, we assessed the occurrence of all these outcomes in hydropic fetuses
compared to those without hydrops at diagnosis. Meta-analyses of proportions using random
effect model and meta-analyses using individual data random-effect logistic regression were
used to combine data.
Results: Eight studies (162 fetuses) were included. The rate of regression was 3.0% (95%CI
0.2–9.1) in fetuses treated and 4.3% (95%CI 0.4–11.8) in those not treated, with no difference
between the two groups (odds ratio (OR): 0.9, 95%CI 0.1–15.1). Pacemaker at birth was required
in 71.5% (95%CI 56.0–84.7) of fetuses-treated and 57.8% (95%CI 40.3–74.3) of those not treated
(OR: 9, 95%CI 0.4–3.4). There was no difference in the overall mortality rate (OR: 0.5, 95%CI
0.9–2.7) between the two groups; in hydropic fetuses, mortality occurred in 76.2% (95%CI
48.0–95.5) of the treated and in 23.8% (95%CI 1.2–62.3) of the untreated group, while in those
without hydrops the corresponding figures were 8.9% (95%CI 2.0–20.3) and 12% (95%CI
8.7–42.2), respectively. Improvement or resolution of hydrops during pregnancy occurred in
76.2% (95%CI 48.0–95.5) of cases treated and in 23.3% (95%CI 1.2–62.3) of those nontreated
with fluorinated steroids.
Conclusions: The findings from this systematic review do not suggest a potential positive contri-
bution of antenatal steroid therapy in improving the outcome of fetuses with immune CAVB.
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Introduction
Atrioventricular block (AVB) encompasses a wide
spectrum of conditions characterized by a delay or
interruption in the transmission of an impulse from
the atria to the ventricles due to an anatomical or
functional impairment in the conduction system [1].
AVB can be a situation where there is no AV conduc-
tion at all, and the atria and ventricles beat inde-
pendently [1].
Complete AVB (CAVB) is the most severe type of
AVB and is associated with high rate of perinatal mor-
tality and morbidity. Slow ventricular rhythm, hydrops,
and early gestational age at birth represent the main
determinants of perinatal outcome in fetuses affected
by CAVB [1–4].
CAVB is usually irreversible; however, some have
suggested that administration of fluorinated steroids
may improve the outcome of these fetuses [5].
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Furthermore, the actual occurrence of hydrops, mortal-
ity, and pacing in fetuses affected by CAVB block has
not been fully elucidated yet. The aim of this system-
atic review was to ascertain the role of maternal ste-
roids therapy in affecting the outcome of fetuses
diagnosed with immune CAVB.
Materials and methods
This review was performed according to a protocol
designed a priori and recommended for systematic
reviews [6]. Medline, Embase, and ClinicalTrials.gov
databases were searched electronically on 24 June
2016 utilizing combinations of the relevant medical
subject heading (MeSH) terms, key words, and word
variants for “complete” or “third degree” fetal heart
block “autoimmune disease” “echocardiography”
“corticosteroids”, and “outcome”. Reference lists of
relevant articles and reviews were hand searched for
additional reports. Before data extraction, the review
was registered with the PROSPERO International
Prospective Register of Systematic Reviews (registra-
tion No: CRD42016045713) following the PRISMA
guidelines for protocols (PRISMA-P) [7].
Only fetuses with immune-mediated CAVB block
and morphologically normal heart diagnosed on pre-
natal ultrasound and treated with fluorinated steroids
compared to those not treated were included. Therapy
with steroids included any type of fluorinated cortico-
steroids used.
Only full text articles were considered eligible for
the inclusion; case reports and conference abstracts
were excluded to avoid publication bias. Furthermore,
only studies published in the last two decades
(1997–2017) were considered suitable for the inclusion,
as we considered that advances in prenatal imaging
techniques, and improvements in the diagnosis and
management of CAVB make these less relevant. Cases
with nonimmune AVB, those for which maternal anti-
body status could not be ascertained and those associ-
ated with major CHD were excluded. Finally, studies
not providing a clear classification of the anomaly
were not considered suitable for the inclusion in the
current review.
Two authors (AC, FD) reviewed all abstracts inde-
pendently. Agreement regarding potential relevance
was reached by consensus with a third reviewer (VB);
full text copies of those articles were obtained and the
same two reviewers independently extracted relevant
data regarding study characteristics and pregnancy
outcome. Inconsistencies were discussed and consen-
sus was reached or the dispute was resolved by dis-
cussion with a third author. If more than one study
was published for the same cohort with identical end-
points, the report containing the most comprehensive
information on the population was included to avoid
overlapping populations. For those articles in which
information was not reported but the methodology
was such that this information would have been
recorded initially, the authors were contacted.
Quality assessment of the included studies was per-
formed using the Newcastle–Ottawa scale (NOS).
According to NOS, each study is judged on three
broad perspectives: the selection of the study groups;
the comparability of the groups; and the ascertain-
ment outcome of interest. Assessment of the selection
of a study includes the evaluation of the representa-
tiveness of the exposed cohort, selection of the nonex-
posed cohort, ascertainment of exposure, and the
demonstration that outcome of interest was not pre-
sent at start of study. Assessment of the comparability
of the study includes the evaluation of the comparabil-
ity of cohorts on the basis of the design or analysis.
Finally, the ascertainment of the outcome of interest
includes the evaluation of the type of the assessment
of the outcome of interest, length, and adequacy of
follow-up. According to NOS, a study can be awarded
a maximum of one star for each numbered item
within the selection and outcome categories. A max-
imum of two stars can be given for comparability [8].
The primary outcome observed was the regression
of the CAVB to either first- or second-degree AVB in
fetuses-treated compared to those not treated with
fluorinated steroids during pregnancy.
The secondary outcomes were:
 Need for pacemaker
 Overall mortality, defined as the occurrence of
either intrauterine (IUD) or neonatal (NND) death.
 IUD
 NND
 Termination of pregnancy (TOP)
We also aimed to stratify the analysis assessing all
the explored outcomes according to the fetal status at
diagnosis (hydrops versus no hydrops) and we eval-
uated whether steroid therapy was associated with an
improvement of hydrops. Furthermore, we planned to
ascertain the occurrence of all the explored outcomes
at either the first electrocardiographic (ECG) assess-
ment after the birth and at follow-up, defined as the
last assessment according to the duration of each
study [1].
For the quantification of the incidence of the out-
come explored, meta-analyses of proportions using
random effect model were used to combine data.
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Funnel plots displaying the outcome rate from individ-
ual studies versus their precision (1/standard error)
were carried out with an exploratory aim. Tests for
funnel plot asymmetry were not used when the total
number of publications included for each outcome
was less than 10. In this case, the power of the tests is
too low to distinguish chance from real asymmetry
[9–12]. Between-study heterogeneity was explored
using the I2 statistic, which represents the percentage
of between-study variation that is due to heterogen-
eity rather than chance [12].
Furthermore, we evaluated separately the risk of
pacemaker insertion, regression, mortality in fetuses-
treated compared to those not treated with steroids
prenatally. We included observational cohort studies in
which: (a) comparisons reported zero events in one
groups; (b) comparisons reported zero events in both
groups; and (c) exposed and unexposed group sizes
were unbalanced. In such a case, many of the most
commonly used meta-analytical methods – including
those using risk differences (which could be used to
handle total zero event studies) – can produce biased
estimates when events are rare [10–12]. When many
studies are also substantially imbalanced, the best per-
forming methods are the Mantel–Haenszel odds ratio
without zero-cell continuity corrections, logistic regres-
sion, and an exact method. Mantel–Haenszel odds
ratios cannot be computed in studies reporting zero
events in both the groups, the exclusion of which
may, however, cause a relevant loss of information
and the potential inflation of the magnitude of the
pooled exposure effect. Therefore, to keep all studies
into the analyses, we performed all meta-analyses
using individual data random-effect logistic regression,
with single study as the cluster unit [10]. The pooled
datasets with individual data were reconstructed using
published 2 2 tables. When one of the overall pooled
arms showed no events, we used exact logistic regres-
sion [10]. Finally, the Wald test was performed in order
to explore the power of the test for each given sample
size.
All analyses were performed using Statsdirect Ltd.
StatsDirect statistical software (England: StatsDirect
Ltd. 2013) and Stata version 13.1 (Stata Corp, College
Station, TX, 2013).
Results
Three hundred and seventy articles were identified, 20
were assessed with respect to their eligibility for inclu-
sion (Supplementary Table 1) and 8 studies included
in the systematic review (Table 1, Figure 1). All preg-
nancies included were positive for SSA/Ro and/or Ta
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SSB/La antibodies; maternal therapy other than fluori-
nated steroids was not described in detail in the
majority of the included studies.
No randomized controlled trial on steroid therapy
versus no such therapy or placebo in fetuses affected
by CAVB was found in the medical databases explored,
thus only nonrandomized studies were included in the
present systematic review. These 8 studies included
162 fetuses with a prenatal diagnosis of immune CAVB
(85 treated and 67 not treated).
Dexamethasone was the fluorinated steroids used
in the vast majority of studies at a preferred dose of
4–8mg/day, although the dose protocol and the ges-
tational age at administration of the drug were not
reported in all the studies included in the review. Type
and timing of postnatal assessment was reported only
by few of the included studies (Table 1); finally, the
type of pacing (permanent versus temporary) adopted
in each study was not specified.
Quality assessment of the included studies per-
formed using Newcastle–Ottawa scale (NOS) for cohort
studies is shown in Table 2. Most of the included stud-
ies showed an overall good rate with regard to the
selection and comparability of the study groups; the
main weaknesses of these studies were their retro-
spective design, small sample size, and a large hetero-
geneity in drug protocol, gestational age at therapy,
and time at follow-up.
Assessment of the risk for each of the outcomes
explored in the present systematic review was prob-
lematic. Only a small proportion of the included stud-
ies reported a direct comparison between fetuses-
treated versus those not treated with steroids, thus
not representing the entire population of fetuses
included in this systematic review (Table 3, Table 4).
Records identified through 
database searching 
(n = 360) 
Sc
re
en
in
g
In
cl
ud
ed
El
ig
ib
ili
ty
Id
en
tif
ic
at
io
n Additional records identified 
through other sources 
(n = 10) 
Records after duplicates removed 
(n = 370) 
Records screened 
(n = 370) 
Records excluded 
(n =350) 
Full-text articles 
assessed for eligibility 
(n = 20)
Full-text articles 
excluded, with reasons 
(n = 12) 
Studies included in 
qualitative synthesis 
(n = 8) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n = 8) 
Figure 1. Systematic review flowchart.
Table 2. Quality assessment of the included studies according
to Newcastle–Ottawa Scale (NOS); a study can be awarded a
maximum of one star for each numbered item within the
selection and outcome categories and a maximum of two
stars can be given for comparability.
Author Year Selection Comparability Outcome
Doti 2016 $ $$ $$
Tunks 2013 $ $ $$
Fesslova 2009 $$ $ $
Friedman 2009 $$ $ $$
Berg 2005 $$ $ $$
Jaeggy 2004 $$ $ $$
Saleeb 1999 $$ $ $
Shinohara 1999 $$ $ $
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The very small number of included cases led to a lack
of statistical power which precluded a comprehensive
assessment of the strength of association between
antenatal steroid therapy and each of the outcomes
observed in the present systematic review. Therefore,
we opted to report the occurrence of outcomes
explored in this systematic review as pooled propor-
tions and then as OR (Tables 3 and 4).
Synthesis of results
Regression
Six studies including 49 cases treated and 45 nontreated
with fluorinated steroids explored the likelihood of
regression to either first or second degree of CAVB. The
rate of regression was 3.0% (95%CI 0.2–9.1) in fetuses-
treated and 4.3% (95%CI 0.4–11.8) in those not treated,
with no significant difference between the two groups
(OR: 0.9, 95%CI 0.1–15.1) (Table 4; Figure 2).
Pacing
Six studies including 40 fetuses-treated and 37 not
treated with fluorinated steroids reported the need for
pacemaker insertion at birth for immune CAVB. In the
group of fetuses-treated with fluorinated steroids ther-
apy the need for pacemaker was 71.5% (95%CI
56.0–84.7) and 57.8% (95%CI 40.3–74.3) in those not
treated, with no statistical difference between the two
groups (OR: 1.09, 95%CI 0.4–3.4) (Table 3 and 4;
Figure 3).
Mortality
The occurrence of either IUD or NND (overall mortality)
was 12.7% (95%CI 5.9–21.6) in fetuses-treated and
12.0% (95%CI 2.9–25.9) in those nontreated with fluori-
nated steroids during pregnancy, with no statistical
difference between the two groups (OR: 0.5, 95%CI
0.9–2.7) (Table 3 and Table 4).
IUD occurred in 11.5% (95%CI 5.1–20.1) of fetuses-
treated and in 10.1% (95%CI 2.9–20.8) of those non-
treated; while the corresponding figures for NND were
3.7% (0.5–9.7) and 5.3% (0.9–13.0), respectively.
Finally, termination of pregnancy was requested in
2.7% (95%CI 0.2–7.9) of women treated with fluori-
nated steroid and 15.0% (95%CI 2.2–36.4) of women in
the untreated group.
Fetal status at presentation (hydropic versus nonhy-
dropic fetuses)
Subanalysis according to fetal status at presentation
was affected by the very small number of included
studies (Supplementary Table 2). In fetuses presenting
with hydrops, pacemaker at birth was needed in all
cases (treated and nontreated) included in the present
systematic review [100% (95%CI 43.9–100)], while in
those without hydrops the corresponding figures for
treated and nontreated cases were 63.5% (95%CI 45.
0–79.8) and 66.2% (95%CI 47.5–82.4), respectively.
There was no case of regression of the AVB in
hydropic fetuses while in nonhydropic fetuses the
regression occurred in 6.4% (95%CI 0–23.8) in the
treated group and 10.6% (95%CI 0.6–30.4).
In fetuses with hydrops, mortality occurred in 76.2%
(95%CI 48.0–95.5) in the treated and 23.8% (95%CI
1.2–62.3) in the untreated group, while the correspond-
ing figures in those without hydrops were 8.9% (95%CI
2.0–þ20.3) and 12% (95%CI 8.7–42.2), respectively.
Table 3. Pooled proportions for the different outcomes observed in this systematic review.
Fetuses treated Fetuses not treated
Outcome Studies Fetuses I2 Pooled % (95%CI) Studies Fetuses I2 Pooled % (95%CI)
Overall regression 6 1/49 0 3.04 (0.2–9.1) 5 1/45 0 4.31 (0.4–11.8)
Need for pacemaker 6 29/40 8.8 71.49 (56.0–84.7) 5 22/37 18.1 57.77 (40.3–74.3)
Mortality (overall) 7 7/64 0 12.66 (5.9–21.6) 6 8/60 52.5 11.97 (2.9–25.9)
IUD 7 6/64 0 11.51 (5.1–20.1) 6 6/60 32 10.07 (2.9–20.8)
NND 6 1/61 0 3.71 (0.5–9.7) 5 2/49 0 5.29 (0.9–13.0)
TOP 7 1/64 0 2.71 (0.2–7.9) 6 10/60 74.7 14.95 (2.2–36.1)
CI: confidence interval; IUD: intrauterine death; NND: neonatal death; TOP: termination of pregnancy.
Table 4. Pooled odd ratios for the need for pacemaker insertion, regression of the block and mortality in
fetuses treated compared to those not treated with fluorinated steroids.
Outcome Studies Fetuses I2 (%) Pooled OR (95%CI)
Overall regression 4 1/49 versus 1/45 – 0.92 (0.1–15.1)
Need for pacemaker 5 26/36 versus 22/37 0 1.09 (0.4–3.4)
Overall mortality 6 7/64 versus 8/60 13.4 0.49 (0.9–2.7)
CI: confidence interval; OR: odds ratio.
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Figure 2. Pooled proportions showing the rate of regression and need for pacemaker in fetuses-treated and in those not treated
with steroid.
Figure 3. Odds ratio for the need of pacemaker in fetuses-treated compared to those not treated with steroids.
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Improvement or resolution of hydrops during
pregnancy occurred in 76.2% (95%CI 48.0–95.5) of
cases treated and in 23.3% (95%CI 1.2–62.3) of those
nontreated with fluorinated steroids (Supplementary
Table 2).
Discussion
The findings from this systematic review show that in
fetuses affected by immune CAVB the chance of
regression is negligible and it is not affected by steroid
therapy. The large majority of fetuses with immune
CAVB require pacemaker insertion at birth, with no dif-
ference between cases treated and nontreated with
fluorinated steroids. Mortality occurs in about 12% of
fetuses affected by CAVB and it is not influenced by
steroids. Finally, fetuses presenting with hydrops are at
generally higher risk of adverse outcome compared to
those not affected.
This is the first meta-analysis assessing the role of
antenatal fluorinated steroids administration in fetuses
affected by immune-mediated CAVB. The strengths of
this study are its robust methodology for identifying
all possible studies for inclusion, assessing data quality,
and synthesizing all suitable data.
The small number of cases in the included studies,
their retrospective nonrandomized design, different
periods of follow-up, lack of information of postnatal
confirmation of the arrhythmia, dissimilarity of the
populations (due to various inclusion criteria), and
the lack of fixed criteria for when to treat represent
the major limitations of this meta-analysis. The assess-
ment of the potential publication bias was also prob-
lematic, both because of the outcome nature (rates
with the left side limited to the value zero) which lim-
its the reliability of funnel plots, and because of the
scarce number of individual studies, which strongly
limits the reliability of formal tests. Many of the
included studies were noncontrolled. The level of evi-
dence for these types of studies is very low.
The very small number of included cases and the
lack of statistical power for all the outcomes explored
in the present systematic review did not allow in esti-
mating the actual strength of association between
antenatal steroid treatment and each of the observed
outcomes. Small sample size of previously published
studies, lack of stratification according to fetal status
at diagnosis, degree of fetal bradycardia, presence of
additional cotreatments either before or after birth,
differences in drug protocols, gestational age at
administration, interval between diagnosis and treat-
ment and length of treatment, and follow-up preclude
to draw any strong objective evidence to guide
management.
A major limitation of the present systematic review
was the lack of stratification according to the degree
of fetal bradycardia. Sustained fetal bradycardia is
associated with a high risk of hydrops, thus limiting
the potential effect of steroids treatment. Lack of
stratification of the analysis according to the interval
between diagnosis and treatment is another major
limitation of the present systematic review. Immune
AVB is characterized by a progressive impairment of
cardiac function and it is entirely possible that cases in
which treatment is started immediately after diagnosis
may experience a better outcome compared to those
in which treatment is delayed. In fact, when fetal
immune heart block is detected at earlier stages, i.e.
second-degree AVB, maternal steroid therapy has been
associated with some benefit in regression or reso-
lution of the AVB, and lower need for pacemaker after
birth [13]. Furthermore, although we have stratified
the analysis according to the presence of hydrops, the
very small number of included cases and the even
smaller number of events did not allow us to perform
any meaningful data synthesis to assess the risk of the
different outcomes in these fetuses compared with
those without hydrops. The presence of other cotreat-
ments was another relevant issue. Often studies deal-
ing with CAVB include fetuses receiving multiple
treatments, such as sympathomimetics, azathioprine,
hydroxychloroquine, and immunoglobulin. Although
cases receiving only multiple treatments were
excluded, it might be entirely possible that cases
including other treatments might have not been men-
tioned in some of the included studies, thus poten-
tially biasing the figures reported. In view of these
limitations, the figures reported in this systematic
review should be interpreted with caution and might
not reflect the actual strength of association between
antenatal steroid therapy and each of the outcomes
observed. Finally, this review was limited by the study
design. Meta-analyses of observational studies are sub-
ject of bias [14–17].
Despite this, the present review represents the best
published estimate of the effect of maternal steroid
therapy for immune CAVB, which can be used to
guide clinical counseling and management. This is
important as counseling for parents based on small
studies that are subject to publication bias may be
inadequate.
Advances in prenatal echocardiography have led to
an increase in the diagnosis of AVB. CAVB is the most
severe type of AVB and is associated with high rate of
perinatal mortality and morbidity. Prenatal diagnosis
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of CAVB in utero relies on the precise assessment of
the heart rhythm and the relationship between atrial
and ventricular depolarization and it is usually accom-
plished by M-Mode or pulsed wave Doppler echocardi-
ography. CAVB is characterized by a slow ventricular
rhythm (usually <60 bpm) in association with AV
dissociation and the atria and ventricles beat
independently [1].
Risk factors for adverse outcome in fetuses affected
by CAVB are fetal hydrops, endocardial fibroelastosis,
premature delivery, and ventricular rate <55 bpm.
In the present systematic review, we found that
about 30% of fetuses with a prenatal diagnosis of
CAVB present with hydrops. Fetuses affected by
hydrops are known to be at higher risk of perinatal
mortality and morbidity compared to those not
affected; furthermore, the presence of hydrops can
affect transplacental passage of steroids, thus limiting
their bioavailability. In the present systematic review,
there was no difference in most of the observed out-
comes between hydropic fetuses treated and not
treated with fluorinated steroids. However, mortality
occurred in 16.7% (95%CI 3.0–56.4) of cases present-
ing with and in 6.9% (95%CI 0.4–20.2) of those with-
out hydrops, irrespective of steroids administration.
These findings concur with those from postnatal
studies, which report high rates of mortality in
hydropic fetuses. Unfortunately, in view of the very
small number of included cases, we could not eluci-
date whether steroid treatment improved survival
rates in those cases presenting with hydrops.
In the present systematic review, we found that
improvement or resolution of hydrops during preg-
nancy occurred in 76.2% (95% CI 48.0–95.5) of cases
treated and in 23.8% (95%CI 1.2–62.2) of those non-
treated with fluorinated steroids (Supplementary Table
2). These figures should be interpreted with caution;
the pathophysiology of hydrops in fetuses affected by
immune CAVB is related to a maladaptation of fetal
heart to sustained bradycardia which leads to ventricu-
lar dilatation, hypertrophy, and subsequent reduction
of the shortening fraction. Fluorinated steroids do not
have any relevant direct effect on ventricular rate;
therefore, it might be entirely possible that the high
rate of resolution of the hydrops was related to the
smaller number of cases of fetuses not treated
included in this review or to the presence of additional
treatments. Beta-mimetics have been anecdotally
reported to increase ventricular rate and improve the
outcome of fetuses affected by CAVB [1], although the
presence of other cotreatments in these cases makes
it difficult to ascertain their actual role in the manage-
ment of this condition.
In conclusion, the findings from this systematic
review do not suggest a potential positive contribution
of antenatal steroid therapy in improving the outcome
of fetuses with immune CAVB. However, in view of all
mentioned limitations, it was not possible to com-
pletely rule out any potential beneficial effect of ste-
roids therapy on the outcome of fetuses affected by
immune CAVB and further evidence is needed before
discouraging steroid administration in this anomaly.
Prenatal counseling of fetuses affected by immune
CAVB should stress the high risk of occurrence of
hydrops and mortality in these fetuses, underling the
very low chance of regression and the need of pace-
maker insertion immediately after birth in the majority
of affected cases.
Large prospective and adequately powered
randomized trials, sharing a common protocol of ante-
natal management, are urgently needed in order to
elucidate the role of maternal fluorinated steroid ther-
apy in modifying the natural history of CAVB in utero.
What’s already known about this topic? Complete
AVB (CAVB) is irreversible, however, some have sug-
gested that administration of fluorinated steroids may
improve the outcome of these fetuses.
What does this study add? The findings from this
systematic review do not suggest a potential positive
contribution of antenatal steroid therapy in improving
the outcome of fetuses with immune CAVB.
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